The minister also added that apart from pandemic and health emergencies, there is an ample scope of collaboration among countries like in the field of vaccine preventable diseases with high morbidity and mortality and for those diseases with no vaccines available currently such as AIDS, TB, etc.
In an application sent to the DCGI on February 9, Srinivas Kosaraju, the head of Quality and Regulatory Affairs of Biological E Limited said the firm had received approval for conducting phase 2/3 clinical study of Corbevax among children and adolescents aged 5-18 years in September.
The court's three liberal justices dissented from the ruling. "When we are wise, we know not to displace the judgments of experts, acting within the sphere Congress marked out and under Presidential control, to deal with emergency conditions," they wrote in the dissenting opinion.
AstraZeneca said this data adds to the growing body of evidence supporting Vaxzevria as a third dose booster, irrespective of the primary vaccination schedules tested.
COVAXIN Booster Dose Data Shows Promising Results
The feature of online appointment for precautionary dose was made operational on the CoWIN portal on Saturday late night. Those eligible to receive precaution dose of Covid vaccines can book online appointment.
The decision came as the Omicron variant is spreading rapidly across the US and has led to record high hospitalisations among younger people.
With the drive starting mostly from schools, many principals and other officials said they received a positive response from students and their families.
The Indian Council of Medical Research also said recently that all Covid vaccines do not prevent infection and are primarily disease-modifying.
WHO Director General issues Strategic Advisory Group of Experts on Immunization’s (SAGE) interim statement on booster doses.
India on Thursday registered 7,495 fresh Covid cases and 434 deaths in a span of 24 hours.
To a query related to Omicron, he said that studies are going on and only after the studies are complete, it will be known which vaccine is how much effective against the new variant.
Meanwhile top US infectious disease expert Anthony Fauci said that early data on the Omicron Covid-19 variant is a "bit encouraging" and does not indicate a great degree of danger, says.
In addition, a significantly higher number of short-lived vaccine reactions were reported in volunteers who received a second dose of Moderna compared to those who received two doses of either AstraZeneca or Pfizer.
The study provides comprehensive data on the real-world vaccine effectiveness and immunological response to vaccination which should help guide policy. The study thus implies that the vaccines continued to be effective in protecting against severe disease and death regardless of the variants.